<DOC>
	<DOCNO>NCT00003582</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug , amifostine , may protect normal cell side effect radiation therapy chemotherapy . PURPOSE : Phase I/II trial study effectiveness radiation therapy plus combination chemotherapy amifostine treat patient stage II , stage III , stage IV head neck cancer surgically remove .</brief_summary>
	<brief_title>Radiation Therapy , Combination Chemotherapy , Amifostine Treating Patients With Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess impact amifostine acute tolerance combine hyperfractionated radiation therapy fluorouracil , cisplatin , paclitaxel amifostine , term grade duration acute mucositis dermatitis , acute hematologic tolerance patient stage III IV unresectable head neck carcinoma . II . Determine local control survival associate regimen patient . III . Determine long term chronic toxic effect regimen term swallow dysfunction , PEG dependency , xerostomia patient . IV . Determine quality life post therapy assessment speech swallow function patient . V. Determine radiation dose escalation patient treatment interruption achieve isoeffect locoregional control . VI . Determine safe optimal dose paclitaxel combine hyperfractionated radiation therapy , fluorouracil , cisplatin , amifostine patient . VII . Determine correlation p53 chromosome expression locoregional control survival patient . VIII . Quantitate tumor volumetrics correlate stage , resectability status , locoregional control survival patient . OUTLINE : This dose escalation paclitaxel , multicenter study . Patients stratify performance status , stage , institution , tumor volumetrics , resectability , p53 expression . Patients receive amifostine IV 10 minute Monday week 1 , 5 , 9 , 5-7 minute Tuesday Friday week 1 , 5 , 9 Monday Friday week 2 , 3 , 4 , 6 , 7 . Within 10-15 minute amifostine administration , patient receive paclitaxel IV 3 hour , cisplatin IV 2 hour day 1 , 29 , 56 , fluorouracil IV 72 hour day 1-4 , 29-33 , 56-60 . Starting day 2 , patient receive hyperfractionated external beam radiotherapy twice daily 6.5 week , follow amifostine IV 5-7 minute Monday Friday . Cohorts 6-20 patient receive escalate dos paclitaxel . Quality life assess . Patients follow monthly 1 year , every 2 month 1 year , every 6 month 3 year , annually thereafter death . PROJECTED ACCRUAL : A minimum 36 patient accrue study within 20 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven squamous cell carcinoma head neck , include : Stage III IV : oral cavity , paranasal sinus , hypopharynx , oropharynx , larynx , nasopharynx OR Unknown primary carcinoma head neck great N1 disease plan neck dissection Evaluable disease No metastases clavicle clinical radiographic diagnosis All hypopharynx nasopharynx patient N3 disease undergo CT scan chest PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Platelet count least 130,000/mm3 WBC least 3,400/mm3 Hemoglobin great 10.0 g/dL ( transfusion allow ) Hepatic : Not specify Renal : Creatinine great 1.4 mg/dL Cardiovascular : No active heart disease No myocardial infarction within past 6 month No uncontrolled congestive heart failure No uncontrolled angina Cardiac ejection fraction least 50 % MUGA scan patient 65 without antecedent heart disease , least 55 % patient 65 and/or antecedent heart disease Pulmonary : FEV great 60 % predict Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy treatment field Surgery : Eligible PEG gastrostomy Other : At least 24 hour since prior antihypertensive diuretic medication ( prior amifostine chemotherapy regimen )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>squamous cell carcinoma unknown primary</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>